CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Taipei, Taiwan and 71 other locations
Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer pa ...
Taipei, Taiwan
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Taipei, Taiwan and 145 other locations
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other ther ...
Phase 1
Taipei, Taiwan and 36 other locations
Olaparib, a PARP inhibitor, is proven as an effective therapy for germline BRCA1/2-mutated breast cancer; however, the therapeutic ...
Phase 2
Taipei, Please Select, Taiwan and 2 other locations
in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast...
Phase 1, Phase 2
Taipei, Taiwan and 31 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Taipei, Taiwan and 446 other locations
how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast...
Phase 3
Taipei, Taiwan and 118 other locations
with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of...
Phase 3
Taipei, Taiwan and 166 other locations
study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast...
Phase 1
Taipei, Taiwan and 73 other locations
Clinical trials
Research sites
Resources
Legal